May Health, a Paris-based medical device startup focusing on helping women living with polycystic ovary syndrome (PCOS) restore ovulation and fertility, has secured $25 million series B funding to scale and advance its Ovarian Rebalancing™ therapy study.
According to the company’s announcement on Monday, May 13, 2024, it secured the new capital through a funding round co-led by Trill Impact and Bpifrance, supported by founding investors Sofinnova Partners, Avestria Ventures and Kidron Capital Assets LP.
As part of the announcement, Nina Rawal, partner at Trill Impact Ventures Advisory, and Jean-Francois Morin, investment director at Bpifrance, will join May Health’s Board of Directors.
May Health will use the additional capital to support its growth and advance its Ovarian Rebalancing™ therapy aimed at restoring natural ovulation in women suffering from PCOS-related infertility.
Currently, the company is undertaking a pivotal REBALANCE Stud to evaluate the effectiveness of the Ovarian Rebalancing™ therapy for women with PCOS-related infertility.
Ovarian Rebalancing™ Therapy
PCOS is a serious life-long endocrine condition stemming from hormone imbalance, and a leading cause of infertility affecting 10% of women globally, according to CDC. The condition usually results in dysregulation of androgens compared to oestrogens in the ovary. This leads to irregular ovulation that may result in PCOS-related infertility.
With the major effect of PCOS being hormonal imbalance, which eventually causes inconsistent ovulation, May Health seeks to treat the condition through its Ovarian Rebalancing— an investigational treatment aimed at restoring natural ovulation cycles.
The therapy, which is still under study, involves a one-time in-office procedure designed to induce ovulation through targeted ablation of ovarian tissue using radiofrequency (RF) energy.
May Health looks forward to evaluating the effectiveness of this therapy through the REBALANCE Study, which will include 15 hospitals across the United States.